TMEM97 and cancer: σ1R antagonists [26,27,28] deactivate the receptor activity, which is anti-apoptotic and neuroprotective [4,16,19,29,30] and σ2R agonists [20,21,22] stimulate the receptor activity and sensitizes cancer cells for apoptosis [21,22,31].